Your session is about to expire
← Back to Search
CXL with MMC for Keratoconus
Phase 2
Waitlist Available
Research Sponsored by Ciusss de L'Est de l'Île de Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month, 3 months, 6 months, 12 months and 18 months post-operation.
Awards & highlights
Summary
This trial tests whether applying a small amount of mitomycin C to the eye can reduce cloudiness and scarring in patients with early-stage corneal disorders who have had corneal crosslinking. The goal is to improve their vision quality by reducing inflammation and scarring. Mitomycin C has been widely used in various eye procedures to minimize scarring and improve outcomes, demonstrating effectiveness in reducing haze and scarring in several studies.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month, 3 months, 6 months, 12 months and 18 months post-operation.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month, 3 months, 6 months, 12 months and 18 months post-operation.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Corneal haze/scarring
Secondary study objectives
Clinical haze grade
Glare
Higher-order aberrations
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: CXL with MMCActive Control1 Intervention
Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).
Group II: CXL without MMCPlacebo Group1 Intervention
Patients who have undergone corneal cross-linking (CXL) without the application of Mitomycin C (MMC).
Find a Location
Who is running the clinical trial?
Ciusss de L'Est de l'Île de MontréalLead Sponsor
77 Previous Clinical Trials
6,333 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger